NASDAQHealth CareMedical - DevicesSnapshot 2026-08-31
Reading DXCM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Dexcom grows sales about 10% a year through 2030. Profit margins improve to about 29-30%. The company keeps gross margins near 67-69%. It also buys back $1 billion of stock. These show strong growth and good cash use.
Growth could slow below 10% a year. Profit margins might stay near 22-23%, below targets. Competition or product issues could hurt sales and margins.
The price is about 15% below our fair value near $87. Analysts expect about 14% revenue growth. Our view aligns with this but sees margin improvement as key upside.
Breaks if: Gross margin falls below 63% beyond FY26
Breaks if: Operating margin remains below 22% beyond FY26
Breaks if: YoY revenue growth falls below 10% in any year through 2030
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent revenue and margin growth. The current thesis state is intact, supported by strong recent financial results and management's commitment to improving profitability.
The market appears to be pricing in a premium compared to peers, reflecting expectations of continued growth. However, there is an expectations gap, indicating that some future performance may not be fully accounted for.
Management is on track to meet its revenue and margin growth targets, with recent results showing strong performance. There is a low probability of missing expectations, but the company must navigate potential industry challenges.
The long-term thesis hinges on maintaining revenue growth and improving margins, as well as external factors such as sector performance and economic conditions. Key triggers include the performance of major healthcare peers and overall market sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The company raised its revenue guidance due to strong demand for glucose monitors. Analysts have also increased their price targets, reflecting confidence in the stock's performance.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Dexcom aims to achieve organic revenue growth of 10%+ every year through 2030.
Breaks if: Share repurchase program is canceled or materially delayed
In the next 1 to 3 years, DXCM's performance will depend on its ability to sustain growth and manage risks effectively. Not investment advice.
